Rapid Method Detects Urinary Tract Infections
|
By LabMedica International staff writers Posted on 22 May 2012 |
The reliability of a rapid detection method for urinary tract infection (UTI) has been compared with the reference standard streaked agar plate method.
The novel CultureStat Rapid UTI Detection System (CSRUDS) consists of a vacuum-sealed glass ampoule containing trypticase soy broth dry media and triphenyl tetrazolium chloride, a chromophore indicator sensitive to dehydrogenase.
Scientists at Columbia University Medical Center, (New York, NY, USA) working with others, selected 980 clean catch urine samples into specimen cups during a 30-day period. Each specimen was streaked on separate 5% sheep blood agar plates and simultaneously a 7-mL aliquot of each fresh urine specimen was processed using the CSRUDS. A spectrophotometer linked to a computer and a bar code scanner was used to identify and test each urine sample.
Positive UTI conditions were accurately identified by both CSRUDS and agar streak plate methods. CSRUDS accurately identified UTI negative conditions with 99.3% reliability at 90 minutes. The negative predictive value of CSRUDS was 99.2% at 30 minutes. The bacterial plating results revealed that 413 (58.8%) of the CSRUDS negative group demonstrated no bacterial growth at all, and 289 (41.2%) of the CSRUDS negative group showed some degree of bacterial growth. Of the 289 samples, 82 (28.4%, including one of the six CSRUDS false-negative samples), showed bacterial growth in the 50,000 colony forming units (CFU) range and 200/289 (69.2%), including the other five false-negative CSRUDS samples, had CFU counts of 1,000-49,000 CFUs or mixed flora. Of the 289, 7 (2.4%) had growth greater than 100,000 colonies/mL.
The author concluded that he novel rapid detection system evaluated in this test program, the CSRUDS and MB80CSENC spectrophotometer (MicroBionetics, Eldersburg, MD, USA) provided UTI negative/positive same-day results within 90 minutes from the start of the test, with a highly reliable negative predictive value within 30 minutes for most patients. Because it is such a rapid test, contamination at urine collection is unlikely to affect the results of the assay. Specimen transport and delays in processing the urine sample are obviated because the test can be immediately performed in the urologist's office where the specimen was collected. The study was published in the April 2012 issue of the journal Urology.
Related Links:
Columbia University Medical Center
MicroBionetics
The novel CultureStat Rapid UTI Detection System (CSRUDS) consists of a vacuum-sealed glass ampoule containing trypticase soy broth dry media and triphenyl tetrazolium chloride, a chromophore indicator sensitive to dehydrogenase.
Scientists at Columbia University Medical Center, (New York, NY, USA) working with others, selected 980 clean catch urine samples into specimen cups during a 30-day period. Each specimen was streaked on separate 5% sheep blood agar plates and simultaneously a 7-mL aliquot of each fresh urine specimen was processed using the CSRUDS. A spectrophotometer linked to a computer and a bar code scanner was used to identify and test each urine sample.
Positive UTI conditions were accurately identified by both CSRUDS and agar streak plate methods. CSRUDS accurately identified UTI negative conditions with 99.3% reliability at 90 minutes. The negative predictive value of CSRUDS was 99.2% at 30 minutes. The bacterial plating results revealed that 413 (58.8%) of the CSRUDS negative group demonstrated no bacterial growth at all, and 289 (41.2%) of the CSRUDS negative group showed some degree of bacterial growth. Of the 289 samples, 82 (28.4%, including one of the six CSRUDS false-negative samples), showed bacterial growth in the 50,000 colony forming units (CFU) range and 200/289 (69.2%), including the other five false-negative CSRUDS samples, had CFU counts of 1,000-49,000 CFUs or mixed flora. Of the 289, 7 (2.4%) had growth greater than 100,000 colonies/mL.
The author concluded that he novel rapid detection system evaluated in this test program, the CSRUDS and MB80CSENC spectrophotometer (MicroBionetics, Eldersburg, MD, USA) provided UTI negative/positive same-day results within 90 minutes from the start of the test, with a highly reliable negative predictive value within 30 minutes for most patients. Because it is such a rapid test, contamination at urine collection is unlikely to affect the results of the assay. Specimen transport and delays in processing the urine sample are obviated because the test can be immediately performed in the urologist's office where the specimen was collected. The study was published in the April 2012 issue of the journal Urology.
Related Links:
Columbia University Medical Center
MicroBionetics
Latest Microbiology News
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








